A team of 30 doctors helped Suze Lopez , 41, deliver her son — and remove the tumor — in a "profound" medical marvel ...

Wistar Institute scientist Maureen Murphy wants to solve a decades-long mystery: Why is ovarian cancer often resistant to hormone therapy? In a recently published study, she shared a new theory as to ...

Hua-Ying Fan, PhD, hopes that her team's latest discovery could help the almost 21,000 people who are expected to receive an ...

July 31, 2025, NEW YORK – The immune system is a major determinant of how patients respond to standard treatments for ovarian cancer, the leading cause of death from gynecological malignancies. But ...

Suze Lopez, a 41-year-old nurse from Bakersfield, was scheduled to have a 22-pound ovarian cyst removed but then discovered that she was pregnant.

Rucaparib maintenance therapy provided consistent benefits across all subgroups of patients grouped by prognostic factors of their homologous recombination deficiency-negative ovarian cancer tumors.

Recent findings published in Scientific Reports highlight a promising target for ovarian cancer drug development, emphasizing ...

High HSP60 expression in ovarian cancer is linked to poor prognosis and aggressive tumor features, including advanced FIGO stage and lymph node metastasis. Patients with elevated HSP60 levels exhibit ...

Ernexa is advancing a best-in-class approach using synthetic, allogeneic iMSCs to provide a scalable, off-the-shelf treatment without needing patient-specific cell harvesting. The Company continues to ...